4//SEC Filing
FRAZIER KENNETH C 4
Accession 0001127602-22-025018
CIK 0000310158other
Filed
Nov 6, 7:00 PM ET
Accepted
Nov 7, 4:06 PM ET
Size
19.2 KB
Accession
0001127602-22-025018
Insider Transaction Report
Form 4
FRAZIER KENNETH C
Exec. VP & President, GHH
Transactions
- Sale
Common Stock
2022-11-03$98.68/sh−214,617$21,178,084→ 721,036.063 total - Exercise/Conversion
Common Stock
2022-11-04+235,000→ 935,653.063 total - Sale
Common Stock
2022-11-04$99.08/sh−34,810$3,448,989→ 700,653.063 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-11-04−235,000→ 235,769 totalExercise: $53.06From: 2017-05-10Exp: 2026-05-09→ Common Stock (235,000 underlying) - Exercise/Conversion
Common Stock
2022-11-03+235,000→ 935,653.063 total - Sale
Common Stock
2022-11-03$99.09/sh−20,383$2,019,804→ 700,653.063 total - Sale
Common Stock
2022-11-04$98.53/sh−200,190$19,725,241→ 735,463.063 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-11-03−235,000→ 470,769 totalExercise: $53.06From: 2017-05-10Exp: 2026-05-09→ Common Stock (235,000 underlying)
Holdings
- 4,481.129(indirect: By 401(k))
Common Stock - 401(k) Plan
Footnotes (7)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.0500 to $99.0500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.0600 to $99.2000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.9700 to $98.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.9800 to $99.2800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
- [F5]Holdings include shares acquired in dividend reinvestment transactions.
- [F6]Includes shares acquired and dividends earned through October 7, 2022 in the Merck U.S. Savings Plan, a 401(k) plan.
- [F7]The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019.
Documents
Issuer
Merck & Co., Inc.
CIK 0000310158
Entity typeother
Related Parties
1- filerCIK 0001181175
Filing Metadata
- Form type
- 4
- Filed
- Nov 6, 7:00 PM ET
- Accepted
- Nov 7, 4:06 PM ET
- Size
- 19.2 KB